Viz.ai, Inc is a leader in applied artificial intelligence in healthcare. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. The flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat. In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification platform. In 2020, Viz LVO became the first AI software to receive approval from CMS. Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Green Oaks, CRV and Threshold Ventures.

 Company Website

Viz CTP: Viz CTP uses advanced imaging technology to automatically analyze CT perfusion images of the brain, produce parametric color maps, and calculate CT perfusion parameters.

Viz ICH: Detect suspected Intracranial hemorrhages

Viz PE: The Viz PE module includes artificial intelligence to automatically detect suspected PEs on CTA imaging and directly alert the on-call PERT team about potentially treatable patients across a multi-hospital network.

Viz AD: The Viz AD module includes artificial intelligence to automatically detect suspected aortic dissection on CTA imaging and directly alert the on-call specialist.